Adagene Inc ADR (ADAG)

Currency in USD
3.210
+0.010(+0.31%)
Closed·
3.170-0.040(-1.25%)
·
ADAG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.9803.470
52 wk Range
1.3004.850
Key Statistics
Prev. Close
3.21
Open
3.2
Day's Range
2.98-3.47
52 wk Range
1.3-4.85
Volume
492.59K
Average Volume (3m)
277.55K
1-Year Change
61.3065%
Book Value / Share
1.35
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ADAG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.908
Upside
+208.67%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Adagene Inc ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.908
(+208.67% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy7.00+118.07%-MaintainSep 14, 2026
Chardan
Buy9.00+180.37%-New CoverageSep 10, 2026
Guggenheim
Buy10.00+211.53%-MaintainJul 14, 2026
H.C. Wainwright
Buy7.00+118.07%-MaintainApr 07, 2026
Guggenheim
Buy10.00+211.53%9.00MaintainApr 06, 2026

Earnings

Latest Release
Aug 12, 2026
EPS / Forecast
-0.23 / -0.19
Revenue / Forecast
1.6M / --
EPS Revisions
Last 90 days

ADAG Income Statement

Compare ADAG to Peers and Sector

Metrics to compare
ADAG
Peers
Sector
Relationship
P/E Ratio
−10.5x−2.5x−0.4x
PEG Ratio
−0.27−0.160.00
Price/Book
2.4x4.1x2.6x
Price / LTM Sales
23.2x15.0x3.1x
Upside (Analyst Target)
208.7%198.8%54.8%
Fair Value Upside
Unlock7.4%7.6%Unlock

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
185.09K0.28%592.28K
Other Institutional Investors
60.60M90.26%193.93M
Public Companies & Retail Investors
6.35M9.46%20.33M
Total
67.14M100.00%214.86M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Han 2020 Irrevocable Trust11.19%7,512,35124,040
Janus Henderson Group Ltd.9.93%6,666,66621,333

People Also Watch

111.56
HALO
-1.18%
9.9600
ADMA
-1.58%
0.308
ATYR
+3.36%
7.45
RGNX
-0.27%
10.81
KURA
+1.89%

FAQ

What Is the Adagene ADR (ADAG) Stock Price Today?

The Adagene ADR stock price today is 3.210 USD.

What Stock Exchange Does Adagene ADR Trade On?

Adagene ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Adagene ADR?

The stock symbol for Adagene ADR is "ADAG."

What Is the Adagene ADR Market Cap?

As of today, Adagene ADR market cap is 214.860M USD.

What Is Adagene ADR's Earnings Per Share (TTM)?

The Adagene ADR EPS (TTM) is -0.395.

When Is the Next Adagene ADR Earnings Date?

Adagene ADR will release its next earnings report on Dec 02, 2026.

From a Technical Analysis Perspective, Is ADAG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Adagene ADR Stock Split?

Adagene ADR has split 0 times.

How Many Employees Does Adagene ADR Have?

Adagene ADR has 128 employees.

What is the current trading status of Adagene ADR (ADAG)?

As of Sep 30, 2026, Adagene ADR (ADAG) is trading at a price of 3.210 USD, with a previous close of 3.210 USD. The stock has fluctuated within a day range of 2.980 USD to 3.470 USD, while its 52-week range spans from 1.300 USD to 4.850 USD.

What Is Adagene ADR (ADAG) Price Target According to Analysts?

The average 12-month price target for Adagene ADR is 9.908 USD, with a high estimate of 17.45 USD and a low estimate of 7 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +208.67% Upside potential.

What Is the ADAG After Hours Price?

ADAG's last after hours stock price is 3.170 USD, the stock has decreased by -0.040, or -1.250%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.